Brean Capital Maintains Buy On OHR Pharmaceutical Following Retinal Society Meeting
In a research report issued today, Brean Capital analyst Jonathan Aschoff maintained a Buy rating on OHR Pharmaceutical Inc (NASDAQ:OHRP) with a $34 price target.
Aschoff said, “At the Retinal Society meeting over the weekend, Ohr presented additional subgroup analysis of interim data from its Phase 2 wet AMD IMPACT trial, notably a K-M curve for time to a sustained 3-line or better gain in mean VA. We look forward to Ohr’s presentation of anatomical data from IMPACT at AAO in late October. Dr. Tom Ciulla will be presenting on October 17 and Dr. Prema Abraham will be presenting on October 18 (as a late breaker), with one of the presentations containing the new anatomical data. The new K-M curve demonstrates that the VA gain of at least 3 lines comes early in a majority of the gainers and that each subsequent time point shows that all achievers maintain the response, with the minority achieving the endpoint at later time points (log rank p-value =0.0370). Maintenance of VA benefit is especially important because this trial was conducted in a PRN Lucentis background where VA fluctuation would be greater than in a background with monthly injections.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Jonathan Aschoff has a total average return of 17.4% and a 58.5% success rate. Aschoff has a 2.9% average return when recommending OHRP, and is ranked #165 out of 3274 analysts.